Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model

Author:

Yamamoto, Jun

Murata, Takuya

Sugisawa, Norihiko

Higuchi, Takashi

Tashiro, Yoshihiko

Nishino, Hiroto

Inubushi, Sachiko

Sun, Y U

Lim, Hyein

Miyake, Kentaro

Shimoya, Koichiro

Nomura, Tsunehisa

Kurebayashi, Junichi

Tanino, Hirokazu

Hozumi, Chihiro

Bouvet, Michael

Singh,Shree Ram

Endo, Itaru

Hoffman, Robert M
Author Address

AntiCancer Inc, San Diego, CA, U.S.A., Department of Surgery, University of California, San Diego, CA, U.S.A., Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Department of Obstetrics and Gynecology 2, Kawasaki Medical School, Okayama, Japan., Department of Obstetrics and Gynecology 1, Kawasaki Medical School, Kurashiki, Japan., Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan., Breast Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan., AntiCancer Japan Inc, Narita, Japan., Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp., Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp., AntiCancer Inc, San Diego, CA, U.S.A. all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp.,

Abstract:

Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model. The PDOX model was established in the left 2nd mammary by surgical orthotopic implantation (SOI). MPBC PDOX models were randomized into 4 groups (6 mice per group) when the tumor volume became 80 mm3: G1, control group; G2, cisplatinum group [intraperitoneal (i.p.) injection, weekly, for 2 weeks]; G3, paclitaxel group (i.p., weekly, for 2 weeks); G4, eribulin group [intravenous (i.v.) injection, weekly, for 2 weeks]. All mice were sacrificed on day 15. Tumor volume and body weight were measured one time per week. The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001). Eribulin has clinical potential for triple-negative MPBC patients. Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

See More

Author Address